(2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol | 745041-64-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol
• 英文别名: (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)nonane-1,3,4-triol；2-azido-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-3,4-O-isopropylidene-D-ribo-1,3,4-nonanetriol；(2S,3R,4S,5S,6R)-2-[(2S)-2-azido-2-[(4S,5R)-2,2-dimethyl-5-pentyl-1,3-dioxolan-4-yl]ethoxy]-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxane
• CAS: 745041-64-9
• 化学式: C₄₆H₅₇N₃O₈
• 分子量: 779.974
• InChiKey: JEHITOMLJHMIOQ-QLINLZFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  57
• 可旋转键数：
  22
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  88.2
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol 在 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-docasanoylamino-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-D-ribo-1,3,4-nonanetriol
  参考文献：
  名称：

  Synthesis and biological evaluation of truncated α-galactosylceramide derivatives focusing on cytokine induction profile

  摘要：

  A series of truncated analogs of alpha-galactosylceramide with altered ceramide moiety was prepared, and evaluated for Th2-biased response in the context of IL-4/IFN-gamma ratio. Phytosphingosine-modified analogs including cyclic, aromatic and ethereal compounds as well as the C-glycoside analog of OCH (2) with their cytokine inducing profile are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.03.025
• 作为产物：
  描述：

  D-Arabitol 在 palladium dihydroxide 吡啶 、 盐酸 、 copper(l) iodide 、 sodium azide 、 三氟化硼乙醚 、 potassium tert-butylate 、 氢气 、 二正丁基氧化锡 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 137.5h， 生成 (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol
  参考文献：
  名称：

  免疫抑制性糖脂（2S，3S，4R）-1 - O-（α-d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇的全合成

  摘要：

  实用有效的全合成（2S，3S，4R）-1- O-（α - d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇OCH 1b（Th1介导的潜在治疗候选物）描述了自身免疫性疾病。该合成将直接烷基化结合到环氧化物5上，并通过立体特异性卤化物离子催化的α-糖基化反应。从市售的d-阿拉伯糖醇2和1b的总合成中，仅需八步即可获得关键中间体10，总收率达到37％。分12步完成，总收率19％。该方法将能够以高度立体选择性的方式合成多种植物鞘氨醇脂，特别是具有比1a短的鞘氨醇侧链的植物鞘氨醇脂。

  DOI：

  10.1021/jo048151y

文献信息

• Synthesis of α-Galactosyl Ceramide (KRN7000) and Analogues Thereof via a Common Precursor and Their Preliminary Biological Assessment
  作者：Mario Michieletti、Antonio Bracci、Federica Compostella、Gennaro De Libero、Lucia Mori、Silvia Fallarini、Grazia Lombardi、Luigi Panza

  DOI：10.1021/jo8019994

  日期：2008.11.21

  practical synthesis of alpha-GalCer and of its analogues is presented, opening the chance to easily modify the sphingosine chain. The common precursor is a disaccharide, obtained by coupling tetra-O-benzyl-D-galactose with allyl 2,3-O-isopropylidene-D-lyxofuranoside. Introduction of alkyl chains via Wittig reaction (for alpha-GalCer and OCH) or via Williamson reaction (for oxa analogues) followed by

  提出了一种新的实用的α-GalCer及其类似物的合成方法，这为轻松修饰鞘氨醇链提供了机会。常见的前体是二糖，其通过将四-O-苄基-D-半乳糖与烯丙基2,3-O-异亚丙基-D-呋喃呋喃糖苷偶联而获得。通过Wittig反应（对于α-GalCer和OCH）或Williamson反应（对于oxa类似物）引入烷基链，然后进行标准合成步骤，可以使人们有效地获得此类化合物。当表达CD1d的细胞呈递时，这些类似物能够激活iNKT细胞。
• Minimum structure requirement of immunomodulatory glycolipids for predominant Th2 cytokine induction and the discovery of non-linear phytosphingosine analogs
  作者：Tetsuya Toba、Kenji Murata、Kyoko Nakanishi、Bitoku Takahashi、Naohiro Takemoto、Minako Akabane、Takashi Nakatsuka、Seiichi Imajo、Takashi Yamamura、Sachiko Miyake、Hirokazu Annoura

  DOI：10.1016/j.bmcl.2007.02.081

  日期：2007.5

  Analogs of immunomodulatory glycolipid OCH (2) were prepared and minimum structure requirement to exhibit equivalent profiles was disclosed. Analogs bearing non-linear hydrocarbon chain in the phytosphingosine moiety (18, 19) were shown for the first time to possess comparable cytokine inducing profile to 2. Molecular modeling of 2/hCD1d complex based on the crystal structure of alpha-GalCer (1)/hCDld complex is also described. (c) 2007 Elsevier Ltd. All rights reserved.
• GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES
  申请人：Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health

  公开号：EP1619199B1

  公开（公告）日：2013-12-18
• Synthesis and biological evaluation of truncated α-galactosylceramide derivatives focusing on cytokine induction profile
  作者：Tetsuya Toba、Kenji Murata、Junko Futamura、Kyoko Nakanishi、Bitoku Takahashi、Naohiro Takemoto、Minako Tomino、Takashi Nakatsuka、Seiichi Imajo、Megumi Goto、Takashi Yamamura、Sachiko Miyake、Hirokazu Annoura

  DOI：10.1016/j.bmc.2012.03.025

  日期：2012.5

  A series of truncated analogs of alpha-galactosylceramide with altered ceramide moiety was prepared, and evaluated for Th2-biased response in the context of IL-4/IFN-gamma ratio. Phytosphingosine-modified analogs including cyclic, aromatic and ethereal compounds as well as the C-glycoside analog of OCH (2) with their cytokine inducing profile are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.
• Total Synthesis of an Immunosuppressive Glycolipid, (<i>2S,3S,4R</i>)-1-<i>O</i>- (α-<scp>d</scp>-Galactosyl)-2- tetracosanoylamino-1,3,4-nonanetriol
  作者：Kenji Murata、Tetsuya Toba、Kyoko Nakanishi、Bitoku Takahashi、Takashi Yamamura、Sachiko Miyake、Hirokazu Annoura

  DOI：10.1021/jo048151y

  日期：2005.3.1

  A practical and efficient total synthesis of (2S,3S,4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonanetriol, OCH 1b, a potential therapeutic candidate for Th1-mediated autoimmune diseases, is described. The synthesis incorporates direct alkylation onto epoxide 5 and stereospecific halide ion catalyzed α-glycosidation reaction. A key intermediate 10 was obtained in only eight steps and 37% overall

  实用有效的全合成（2S，3S，4R）-1- O-（α - d-半乳糖基）-2-四cosanoylamino-1,3,4-壬三醇OCH 1b（Th1介导的潜在治疗候选物）描述了自身免疫性疾病。该合成将直接烷基化结合到环氧化物5上，并通过立体特异性卤化物离子催化的α-糖基化反应。从市售的d-阿拉伯糖醇2和1b的总合成中，仅需八步即可获得关键中间体10，总收率达到37％。分12步完成，总收率19％。该方法将能够以高度立体选择性的方式合成多种植物鞘氨醇脂，特别是具有比1a短的鞘氨醇侧链的植物鞘氨醇脂。